We are live on
!
Find out more
E Fund Management Portfolio holdings
AUM
$4.46B
Turnover
13.19%
This Fund
S&P 500
This Quarter
Est. Return
+6.51%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.95B
AUM Growth
+$137M
(+7.6%)
Cap. Flow
+$63.5M
Cap. Flow
% of AUM
3.26%
Top 10 Holdings %
Top 10 Hldgs %
62.7%
Holding
375
New
57
Increased
197
Reduced
86
Closed
22
Avg Time Held
2
years
Top 10 Avg Time Held
1.3
years
Top 20 Avg Time Held
1.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$12.1M |
| 2 |
Apple
AAPL
|
+$11.7M |
| 3 |
NVIDIA
NVDA
|
+$9.16M |
| 4 |
Broadcom
AVGO
|
+$6.03M |
| 5 |
Pinduoduo
PDD
|
+$5.45M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ASE Group
ASX
|
+$18.3M |
| 2 |
Sea Limited
SE
|
+$11.3M |
| 3 |
TSMC
TSM
|
+$9.27M |
| 4 |
ZTO Express
ZTO
|
+$7.08M |
| 5 |
NIO
NIO
|
+$4.53M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 37.74% |
| 2 | Technology | 30.94% |
| 3 | Communication Services | 8.5% |
| 4 | Healthcare | 6.31% |
| 5 | Financials | 5.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
126
Fate Therapeutics
FATE
$217M
| $1.24M | 0.06% |
353,771
-1,454
| -0.4% | -$5.66K |
2024 Q1
2 quarters
|
|
127
Idexx Laboratories
IDXX
$44B
| $1.23M | 0.06% |
2,434
+1,101
| +83% | +$535K |
2021 Q1
14 quarters
|
|
128
Automatic Data Processing
ADP
$113B
| $1.22M | 0.06% |
4,417
+306
| +7% | +$80K |
2021 Q1
14 quarters
|
|
129
Airbnb
ABNB
$101B
| $1.2M | 0.06% |
9,471
+4,002
| +73% | +$519K |
2021 Q4
11 quarters
|
|
130
Gartner
IT
$12.9B
| $1.2M | 0.06% |
2,364
+1,250
| +112% | +$601K |
2021 Q1
14 quarters
|
|
131
Starbucks
SBUX
$111B
| $1.19M | 0.06% |
12,236
+889
| +8% | +$76.3K |
2021 Q1
14 quarters
|
|
132
United Therapeutics
UTHR
$22.7B
| $1.15M | 0.06% |
3,204
-704
| -18% | -$238K |
2022 Q1
10 quarters
|
|
133
Amphenol
APH
$196B
| $1.13M | 0.06% |
34,810
-23,054
| -40% | -$747K |
2021 Q1
14 quarters
|
|
134
DELISTED
Exact Sciences
EXAS
| $1.13M | 0.06% |
16,576
-10,303
| -38% | -$581K |
2022 Q1
10 quarters
|
|
135
Natera
NTRA
$56.6B
| $1.09M | 0.06% |
8,587
-1,392
| -14% | -$160K |
2022 Q1
10 quarters
|
|
136
Sarepta Therapeutics
SRPT
$1.81B
| $1.09M | 0.06% |
8,716
-45
| -0.5% | -$6.22K |
2022 Q1
10 quarters
|
|
137
Palantir
PLTR
$448B
| $1.08M | 0.06% |
+29,063
| New | +$892K |
2024 Q3
0 quarters
|
|
138
Mondelez International
MDLZ
$81.4B
| $1.07M | 0.05% |
14,467
+619
| +4% | +$43.5K |
2021 Q1
14 quarters
|
|
139
Insmed
INSM
$21B
| $1.06M | 0.05% |
14,551
+7,736
| +114% | +$571K |
2022 Q1
10 quarters
|
|
140
Monster Beverage
MNST
$89.2B
| $1.04M | 0.05% |
39,920
+19,930
| +100% | +$494K |
2021 Q1
14 quarters
|
|
141
Viking Therapeutics
VKTX
$3.2B
| $1.03M | 0.05% |
16,280
-4,100
| -20% | -$241K |
2023 Q1
6 quarters
|
|
142
Deckers Outdoor
DECK
$11.6B
| $1.03M | 0.05% |
6,460
-12,530
| -66% | -$1.91M |
2023 Q4
3 quarters
|
|
143
S&P Global
SPGI
$126B
| $1.03M | 0.05% |
1,991
+236
| +13% | +$117K |
2024 Q1
2 quarters
|
|
144
Neurocrine Biosciences
NBIX
$13.8B
| $1.02M | 0.05% |
8,887
+1,568
| +21% | +$215K |
2022 Q1
10 quarters
|
|
145
Microchip Technology
MCHP
$40.2B
| $1.01M | 0.05% |
12,614
+1,771
| +16% | +$146K |
2021 Q1
14 quarters
|
|
146
Carnival Corporation Ltd
CCL
$34.7B
| $999K | 0.05% |
54,076
+27,038
| +100% | +$458K |
2023 Q4
3 quarters
|
|
147
RH
RH
$2.14B
| $995K | 0.05% |
2,974
+395
| +15% | +$109K |
2024 Q1
2 quarters
|
|
148
IQVIA
IQV
$43.4B
| $994K | 0.05% |
4,193
+3,106
| +286% | +$733K |
2023 Q4
3 quarters
|
|
149
GE Vernova
GEV
$246B
| $953K | 0.05% |
+3,739
| New | +$718K |
2024 Q3
0 quarters
|
|
150
Kyverna Therapeutics
KYTX
$354M
| $926K | 0.05% |
189,432
| – | – |
2024 Q2
1 quarter
|
|
Similar funds
E Fund Management's Q3 2024 Portfolio in Review
As of Q3 2024, E Fund Management held 375 positions worth $1.95B, up 7.6% from $1.81B the previous quarter. Its ten largest holdings account for 63% of the portfolio.
E Fund Management deployed $63.5M of net new capital in Q3 2024, opening 57 new positions and adding to 197 existing holdings. Its largest new stake was argenx: 5,800 shares worth $3.14M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 38% of assets, down from 40% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was TSMC, an estimated $9.27M trimmed.
- E Fund Management's largest Q3 2024 buy was argenx: 5,800 shares worth $3.14M.
- E Fund Management added most to Microsoft in Q3 2024, an estimated $12.1M increase.
- E Fund Management's biggest Q3 2024 reduction was TSMC, cutting an estimated $9.27M.
- E Fund Management fully exited ASE Group in Q3 2024, selling an estimated $18.3M.
- E Fund Management's ten largest holdings make up 63% of its $1.95B portfolio in Q3 2024.
- E Fund Management opened 57 new positions and closed 22 in Q3 2024.
- E Fund Management's portfolio value rose 7.6% quarter-over-quarter to $1.95B.
Based on E Fund Management's 13F filing for Q3 2024, filed 13 Nov 2024.